Trial Profile
Multicenter, open-label safety study of serlopitant in adults for the treatment of pruritus associated with prurigo nodularis, atopic dermatitis, or psoriasis.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Serlopitant (Primary)
- Indications Pertussis
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2018 According to Menlo Therapeutics media release, study is fully enrolled, and the Company expects to report top-line data in December 2018.
- 04 Apr 2018 New trial record